

Objective: To identify post-hoc predictors of overall survival, including subsequent treatment modalities, in men previously randomized to prednisone + abiraterone or prednisone + placebo.

Methods Used: No analyses were conducted. Data was not accessed.

Results: None

Conclusions: N/A